Author

Ying Qu

Army Medical University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1

Frequent Co-Authors

Ce DouiD· 1 shared Chunxia Ao· 1 shared Fei LuoiD· 1 shared Feng ZhouiD· 1 shared Gang Liu· 1 shared Jiajia LiiD· 1 shared Jie Shen· 1 shared Jie Zhang· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCell Biology

Ce DouORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Efferocytosis Remodels Osteoclast Metabolism and Enhances Antibacterial Defense

Qixiu Yu, Jie Zhang, Ying Qu, Yong Tang, Yuyang Zhang, Yewei Jia, Qijie Dai, Zhoukai Huang, Jie Shen, Nathachit Limjunyawong, Fei Luo, Ce Dou

This study shows that osteoclast efferocytosis enhances antibacterial defense by remodeling metabolism through glycolytic activity and lactate handling.

bioRxiv · Oct 16, 2026 · PreprintCell Biology

ZMS-6659, a selective Polθ helicase inhibitor, demonstrates anti-tumor activity as monotherapy and synergy effect with PARP inhibitors and topoisomerase inhibitors

Lei Jiang, Jiajia Li, Lu Liu, Mengying Li, Wenjing Li, Zhen Li, Shuo Qian, Mingyue Shi, Jing Dai, Chunxia Ao, Ying Qu, Zhengtao Li, Li Zhou, Yang Chen, Xiyuan Wang, , Liting Xue

ZMS-6659, a Polθ helicase inhibitor, shows anti-tumor activity as monotherapy and synergizes with PARP inhibitors and topoisomerase inhibitors in HR-deficient and HR-proficient models.

bioRxiv · Apr 19, 2025 · PreprintCancer Biology